OnKure Therapeutics, a newly formed company, has emerged as a potential player in the breast cancer treatment market with its novel drug OKI-219. This third-generation PI3Kα inhibitor aims to address the limitations of current treatments, particularly the toxicity associated with alpelisib. The analyst at Oppenheimer initiates coverage with an Outperform rating, citing the significant market opportunity and the potential for OKI-219 to become a leading treatment option for breast cancer patients with specific mutations.